This website uses cookies to improve functionality and performance. With a click on the OK button you are giving implied consent to the use of cookies on this website.
More information
EnglishDeutsch
de
EnglishDeutsch
de
Login Environment Pharma

SYNLAB pharma supports regional, international and global clinical trials

Phase I

Phase I studies, especially first in man studies, require immediate laboratory testing not just for safety parameters but also for an increasingly wide range of cellular and soluble biomarkers.

SYNLAB pharma offers local laboratory solutions across Europe for rapid testing; 24 hours per day, 365 days per year.

In addition, SYNLAB pharma has dedicated laboratory facilities with world-class expertise and state of the art equipment for bioanalysis to support SAD, MAD or DDI studies. We operate a state-of -the-art facility for bioanalysis of small molecules and biopharmaceuticals (LC-MS/MS and ligand-binding assays) in Switzerland - and deliver your study results with Swiss quality and timelines.

Phase II to IVCentral Lab Services - Worldwide

In addition to the services above, SYNLAB pharma provides regional, international and global central laboratory services for clinical trials run by pharmaceutical and biotech companies as well as by CROs.

Paediatric studies

For paediatric studies (PIP) SYNLAB pharma provides age specific visit kits (including microtainers), sample collection systems (e.g. DBS cards) and analytical methods designed to analyse microvolumes.

Contact us



News & Events

View All
Fellbach wird neuer Laborstandort
Nach zweijähriger Planungs- und Umbauphase entstand in Fellbach das neue Labor der SYNLAB Analytics & Services Germany GmbH.
Aug 10, 2018 Continue
Determination of the Impurity N-Nitroso dimethyl amine (NDMA) in Drug Substances with GC-MS

Due to contamination of a drug substance with the potential mutagenic substance N-Nitroso dimethyl amine (NDMA) a massive recall campaign was initiated for the related drug products. SYNLAB Pharma offers a GC-MS test for testing the absence of NDMA in drug substances and drug products.

Please contact our experts.

Jul 13, 2018 | Pharma Continue
New Services in Regulatory Compliance for Biologics

With immediate effect, SYNLAB Pharma provides a broad support in the field of Regulatory Compliance of Biologics development. With this new services we support specifically start-ups, small to medium sized biotech companies, which require professional consultancy and project execution in regulatory project design.

For further questions, please contact:

pharma@synlab.com

Jun 18, 2018 | Pharma Continue
View All